Her's some snippets from last two days wsj on the web
Go DUSA!! I bought at $7 about 6 months back
DUSA announcedpositive Phase II clinical trial results for its topical ALA Photodynamic Therapy (ALA
PDT) for precancerous, actinic keratoses of the face and scalp.
The company said the study represents the first use of its non-laser blue light source,
which can treat an entire face or scalp at once.
With data available on 36 patients, at the optimal light dosage, about 90% of treated
lesions cleared completely after a single treatment. The few remaining lesions cleared
after a second treatment, leading to an overall complete response rate of 100% at that
dosage. The overall placebo response rate was 26%, the company said.
It said that, in the study, 36 patients had four discrete lesions of the face or scalp
randomized to receive 20% ALA solution or placebo. The patients then were randomized
to receive a specified light dose to all four lesions simultaneously, using DUSA's
proprietary light source. An investigator who was unaware of the patients' treatment, then
made objective measurements of the lesions at weeks one, four and eight. If lesions
remained at week eight, they were treated again, and re-examined at weeks 12 and 16.
MISSISSAUGA, Ont. (Dow Jones)--DUSA Pharmaceuticals Inc. (DUSA) and MeL-Co
said they have launched Lipomelanin-LQ, a synthetic melanin specifically designed for
use as a black hair coloring agent.
MeL-Co, an independent firm based in Orland, Calif., is producing Lipomelanin-LQ,
and marketing it to cosmetic and hair care companies for use in semi-permanent hair
dyes, coloring shampoos and coloring creme rinses.
The product is currently undergoing testing by a major European company, the companies
said.
Black hair dye products are widely used around the world. However, there has been
controversy over the use of certain coal tar derived black hair dye ingredients, which have
been found to cause cancer in laboratory animals. Lipomelanin-LQ may provide an
alternative to these ingredients, the companies said.
Lipomelanin-LQ is the first product of a collaboration between DUSA and MeL-Co to
develop a series of Lipomelanin compounds for use in over-the-counter and/or cosmetic
products.
The rights to these compounds were licensed by DUSA from inventors at the University
of Toronto, and have been developed for DUSA by MeL-Co, a melanin specialty
company.
DUSA is a development stage pharmaceutical company. |
